AutoCell HSC Platform for SCD/beta-thalassemia
Sickle Cell Disease, beta-thalassemia
Pre-clinicalActive
Key Facts
Indication
Sickle Cell Disease, beta-thalassemia
Phase
Pre-clinical
Status
Active
Company
About Trenchant Biosystems
Trenchant Biosystems is a private, pre-revenue biotech platform company developing automated manufacturing solutions for the cell and gene therapy (CGT) industry. Its flagship AutoCell platform utilizes a microbubble separation technology as an alternative to traditional methods, designed to operate with a small footprint at the point-of-care to significantly reduce costs and complexity. The company is advancing its technology through a key alliance with UMass Chan Medical School and Caring Cross, targeting sickle cell disease and beta-thalassemia, with plans for an IND-enabling studies and a clinical trial start in 2027.
View full company profile